Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.72 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.72 |
| ▸ | NR3C2 | P08235 | 3/20 | 0.72 |
| ▸ | SHBG | P04278 | 3/20 | 0.72 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | BLM | P54132 | 1/20 | 0.72 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.72 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.72 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | MTOR | P42345 | 1/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2175877 | 1.00 | SMN1; SMN2 (0.72) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL8668291 | 0.91 | SMN1; SMN2 (0.80) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL8668298 | 0.91 | SMN1; SMN2 (0.80) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL13449676 | 0.90 | SMN1; SMN2 (0.70) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL11125549 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL11125553 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL11125542 | 0.85 | SMN1; SMN2 (0.61) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL4110734 | 0.84 | CYP3A4 (0.70) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL13752943 | 0.84 | CYP3A4 (0.70) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 | |
| SCHEMBL4110739 | 0.84 | CYP3A4 (0.70) | SMN1; SMN2CYP3A4HIF1ALMNACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 210 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | ZALICUS INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20120028910-A1 | STORAGE-STABLE AQUEOUS OPHTHALMIC FORMULATIONS | FOVEA PHARMACEUTICALS (FR) | 2012-02-02 | — | — | US | claimed |
| US-8080553-B2 | Methods and reagents for the treatment of immunoinflammatory disorders | ZALICUS INC. (US) | 2011-12-20 | — | — | US | claimed |
| EP-2301628-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | Zalicus Inc. (US) | 2011-03-30 | — | — | EP | claimed |
| EP-2070550-A1 | Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases | Combinatorx, Incorporated (US) | 2009-06-17 | — | — | EP | claimed |
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | COMBINATORX INC. (US) | 2007-01-11 | — | — | US | claimed |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | STELLULAR BIO, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | CORCEPT THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| EP-4434584-A2 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | Corcept Therapeutics Incorporated (US) | 2024-09-25 | — | — | EP | disclosed |
| EP-4119561-B1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230174939-A1 | NOVEL ANUCLEATED CELLS AS A SOURCE FOR TREATMENT OF PLATELET RICH PLASMA DEPENDENT DISORDERS | STELLULAR BIO, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| EP-1051479-A4 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | SALK INST FOR BIOLOGICAL STUDI (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1235861-A2 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2002-09-04 | — | — | EP | disclosed |
| US-6274118-B1 | INJECTING PATIENT HAVING ENDOCRINE CANCER IN NON-PROSTATIC TISSUE WITH BIOLOGICAL BINDING UNITS WHICH BIND TO PROSTATE SPECIFIC ANTIGEN PRODUCED BY NON-PROSTATIC TISSUE | NORDION INTERNATIONAL INC. (CA) | 2001-08-14 | — | — | US | disclosed |
| WO-2001042290-A2 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-1051479-A1 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2000-11-15 | — | — | EP | disclosed |
| WO-1999035246-A9 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | SALK INST FOR BIOLOGICAL STUDI (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999035246-A1 | NOVEL STEROID-ACTIVATED NUCLEAR RECEPTORS AND USES THEREFOR | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 1999-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010502-A1 | Methods and reagents for the treatment of immunoinflammatory disorders | IL5, TPMT, TSLP | SMN1; SMN2 1541/4885CYP3A4 1322/4885HIF1A 1602/4885 |
| US-20250099457-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | SMN1; SMN2 181/4885CYP3A4 1984/4885HIF1A 4622/4885 |
| US-12226412-B2 | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | NR3C1, GRIN3A, NR3C2 | SMN1; SMN2 181/4885CYP3A4 1984/4885HIF1A 4622/4885 |
| US-20260124244-A1 | MEGAKARYOCYTE DERIVATIVES FOR TREATMENT OF DRY EYE DISEASES | MYH10, PDGFA, MPL | SMN1; SMN2 1472/4885CYP3A4 2902/4885HIF1A 1864/4885 |
| US-20120058979-A1 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | IL5, TPMT, TSLP | SMN1; SMN2 1541/4885CYP3A4 1322/4885HIF1A 1602/4885 |
| US-20230330084-A1 | HETEROARYL-KETONE FUSED AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS | NR3C1, GRIN3A, NR3C2 | SMN1; SMN2 181/4885CYP3A4 1984/4885HIF1A 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.